Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial
Agata Blasiak, Anh T. L. Truong, Nigel Foo, Lester W. J. Tan, Kirthika Senthil Kumar, Shi‐Bei Tan, Chong Boon Teo, Benjamin Y. L. Tan, Xavier Tadeo, Hon Lyn Tan, Cheng Ean Chee, Wei Peng Yong, Dean Ho, Raghav Sundar
Abstract
In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a patient's own, small dataset to dynamically personalize only their own dose recommendations. The primary objective of this feasibility trial was to assess the logistical and scientific feasibility of providing dynamically personalized AI-derived chemotherapy dose recommendations for patients with advanced solid tumors at/for treatment with single-agent capecitabine, capecitabine in combination with oxaliplatin (XELOX), or capecitabine in combination with irinotecan (XELIRI). CURATE.AI demonstrated adaptability to clinically relevant situations encountered by patients often treated with palliative intent of care. High rates of user adherence were demonstrated, which could be in part due to the high engagement of the physicians in selecting data and boundaries for CURATE.AI operations.